Affinity Asset Advisors, LLC Intellia Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$58.27 - $118.99 $582,700 - $1.19 Million
-10,000 Closed
0 $0
Q4 2021

Feb 11, 2022
SELL
$100.76 - $138.36 $503,800 - $691,800
-5,000 Reduced 33.33%
10,000 $1.18 Million
Q3 2021

Nov 12, 2021
BUY
$132.37 - $176.78 $661,850 - $883,900
5,000 Added 50.0%
15,000 $2.01 Million
Q2 2021

Aug 13, 2021
BUY
$60.88 - $161.91 $608,800 - $1.62 Million
10,000 New
10,000 $1.62 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email